ArticleAmerican journal of translational research2025
Effects of Leuprorelin combined with Mirena on endocrine function, emotion, quality of life, and endometrial receptivity in patients with adenomyosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the combined effects of Leuprorelin and Mirena on endocrine profiles, emotional well-being, quality of life, and endometrial receptivity (ER) in patients with adenomyosis.
methodsThis is a retrospective cohort study involving 144 patients with adenomyosis, in which 81 received Mirena alone and 63 received the combination of Mirena and Leuprorelin. Primary outcomes included menstrual volume, dysmenorrhea, uterine volume, hormone levels, emotional status, quality of life, and ER, assessed via clinical scales and ultrasound.
resultsCombination therapy significantly reduced menstrual volume, dysmenorrhea, and uterine volume compared to Mirena alone (all P < 0.05). Endocrine hormone levels were notably lower in the combination group (P < 0.05). Anxiety improved significantly (P = 0.012), with trends toward improved depression outcomes. Psychological health and social quality of life also showed significant improvement (P < 0.05). ER was enhanced, with better endometrial characteristics and blood flow (P < 0.05). Adverse events were similar between groups.
conclusionThe combination of Leuprorelin and Mirena offers superior efficacy over Mirena alone in managing adenomyosis. This regimen provides enhanced symptom relief, reduces endocrine disruptions, and improves emotional well-being and quality of life without increasing adverse events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.